3 results
Approved WMOCompleted
To determine the maximum tolerated dose, dose limiting toxicity and recommended Phase 2 dose of BMS-753493 in subjects with advanced cancer.
Approved WMOCompleted
The primary objective of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic NSCLC patients naive to ALK inhibitors, as evidenced by PFS.The secondary objectives of the study are:1. To…
Approved WMOCompleted
The aim of the FAST OCT study is to define the correlation between 3D-angio-based FFR values and OCT findings in a pre- and post-PCI setting in patients with non-ST segment elevation acute coronary syndromes (NST-ACS). The results will be used to…